Evidence map›Paper›PMID 40906111›Full record

ArticleBiology2025

Real-Time Functional Stratification of Tumor Cell Lines Using a Non-Cytotoxic Phospholipoproteomic Platform: A Label-Free Ex Vivo Model.

Ramón Gutiérrez-Sandoval, Francisco Gutiérrez-Castro, Natalia Muñoz-Godoy, Ider Rivadeneira, Adolay Sobarzo, Jordan Iturra, Ignacio Muñoz, Cristián Peña-Vargas, Matías Vidal, Francisco Krakowiak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ramón Gutiérrez-SandovalDepartment of Oncopathology, OGRD Alliance, Lewes, DE 19958, USA.ORCID 0009-0004-8428-9549
Francisco Gutiérrez-CastroCancer Research Department, Flowinmunocell-Bioexocell Group, 08028 Barcelona, Spain.
Natalia Muñoz-GodoyCancer Research Department, Flowinmunocell-Bioexocell Group, 08028 Barcelona, Spain.
Ider RivadeneiraOutreach and Engagement Programs Department for the OGRD Consortium, Charlestown KN0802, Saint Kitts and Nevis.
Adolay SobarzoDepartamento de Ciencias Biológicas y Químicas, Facultad de Ciencias, Universidad San Sebastián, Lientur 1457, Concepción 4080871, Chile.
Jordan IturraOutreach and Engagement Programs Department for the OGRD Consortium, Charlestown KN0802, Saint Kitts and Nevis.
Ignacio MuñozOutreach and Engagement Programs Department for the OGRD Consortium, Charlestown KN0802, Saint Kitts and Nevis.
Cristián Peña-VargasDepartment of Oncopathology, OGRD Alliance, Lewes, DE 19958, USA.
Matías VidalDepartment of Oncopathology, OGRD Alliance, Lewes, DE 19958, USA.
Francisco KrakowiakDepartment of Molecular Oncopathology, Bioclas, Concepción 4030000, Chile.

Funding

Fundación Biotech FB-20222-0871
6 · The paper itself

Abstract

The development of scalable, non-invasive tools to assess tumor responsiveness to structurally active immunoformulations remains a critical unmet need in solid tumor immunotherapy. Here, we introduce a real-time, ex vivo functional system to classify tumor cell lines exposed to a phospholipoproteomic platform, without relying on cytotoxicity, co-culture systems, or molecular profiling. Tumor cells were monitored using IncuCyte

Indexed as

batch-level documentationearly-stage regulatory validationex vivo immunoprofilingfunctional tumor stratificationIFN-γ/IL-10 ratioimmunophenotypic classificationnon-cytotoxic kinetic modelingphospholipoproteomic platformSTIP traceability systemstructural immunomodulation

Identifiers

PMID40906111
PMCPMC12383301

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.